A Phase II Study of Everolimus in Patients with FDG-PET Positive Intermediate Grade (Ki67 3-20%) Pancreatic Neuroendocrine Tumor Abstract #1158

Introduction: The RADIANT-3 trial showed Everolimus (EV), as active in patients (pts) with progressive well/intermediate grade PNETs. Intermediate/grade 2 (Ki67 3-20%) PNETs have variable biology. FDG-PET avidity is an independent negative factor for survival, consistent with aggressive disease biology- but such imaging is not used to select treatment as in the case of the RADIANT 3 trial.
Aim(s): Assess the activity of EV as first-line therapy in patients with FDG-avid intermediate/grade 2 PNETs.
Materials and methods: Eligible pts had newly diagnosed FDG-PET-avid grade 2 advanced PNET with measurable/ evaluable disease. ECOG PS 0-2. Adequate organ function. No prior systemic therapy for PNETs. Pts received EV 10mg po daily until disease progression. Pts were staged every 12 weeks with structural imaging/FDG and Gal-DOTA PET. Primary endpoint was PFS at 6 months. PET/structural imaging response rate, response duration, toxicity and QOL were also measured.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: ASSOC PROF Michael Michael
Keywords: everolimus, FDG-PET

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1381 [18F]FDG-PET/CT as a Predictive Tool for Response to Chemotherapy and Everolimus Treatment in Patientes with Pancreatic Neuroendocrine Tumour
Introduction: The predictive role of 18F-FDG-PET/CT (FP) in neuroendocrine tumours is debated.
Conference: 13th Annual ENETS conference (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD Silvia Ortolani
#912 Serial 89Zr-bevacizumab PET in Patients with Neuroendocrine Tumors before and on Everolimus Treatment
Introduction: Everolimus increases PFS in patients with advanced NETs. Currently, no biomarkers are available for early selection of patients who will benefit from everolimus. Everolimus can reduce VEGF-A production by tumor cells.
Conference: 11th Annual ENETS Conference (2014)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD, PhD Adrienne H Brouwers
#1557 Dual High Throughput Proteomic and Transcriptomic Screen for Predictive Biomarkers of Everolimus Sensitivity in Pancreatic NET
Introduction: mTOR inhibitor Everolimus is approved for the treatment of well-differentiated PNET. The heterogeneity of the response rate and the potential toxicity warrant predictive biomarkers.
Conference: 13th Annual ENETS conference (2016)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Dr Jerome Cros
Authors: Bucau M, Cros J, Raffenne J, Rebours V, ...
#871 Success with Lutetium-177 DOTATATE Therapy in Cushing’s Syndrome Caused by Functional Pancreatic Neuroendocrine Tumor (pNET) with Ectopic Adrenocorticotropic Hormone (ACTH) Secretion Refractory to Concomitant Everolimus, Pasireotide and Metyrapone
Introduction: We report a case of a 59-year-old female presenting with florid ACTH-dependent Cushing’s syndrome complicated by pulmonary cryptococcal infection.
Conference: 11th Annual ENETS Conference (2014)
Category: Clinical cases/reports
Presenting Author: Dr Bryan A Chan
Authors: Chan B A, Wyld D, Burge M, Cuneo R, ...
#918 Hyperinsulinemic Hypoglycemia by an Ovarian Germ Cell Tumor
Introduction: A 76-yr-old woman was admitted to our department for recurrent hot flushes, sweating and dizziness associated with fasting hypoglycemia. Physical examination revealed abdominal obesity and ascites.
Conference: 11th Annual ENETS Conference (2014)
Category: Clinical cases/reports
Presenting Author: Marialberta Battocchio
Keywords: ovary, insulin, SSA, everolimus
Close
Notice
Important Notice:

In preparation of the upcoming ENETS Barcelona 2018 Annual Conference, we have discovered in the world wide web at least one professional entity suggestive of possessing an ENETS mandate for conference registrations. Therefore, we must inform you that 100% of all conference participants are registered through ENETS official website www.enets.org and http://enetsconference.org/. There are no further options to validly register for Barcelona 2018 (or for any other ENETS event).

Please stay away from fraudulent scams abusing the ENETS acronym to register – and charge you above official ENETS conference fees! Such entities, against whom ENETS presses criminal charges, are neither authorized, nor commissioned nor instructed by ENETS to make such representations.